GSK/Corixa Bexxar NDA
Executive Summary
Corixa/GlaxoSmithKline's Bexxar (tositumomab) could receive review for treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma by FDA's Oncologic Drugs Advisory Committee at the tentatively scheduled Sept. 23-24 meeting. Corixa requested committee review of the drug in its appeal of a March 12 "complete review" letter (1"The Pink Sheet" May 20, In Brief)...